Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1591-1600 Newer>

The Motley Fool December 6, 2004 W.D. Crotty	Boom and Bust for Two Biotechs Biotechnology, is high risk. Nothing demonstrated the bust cycle better than today's stock market action in Genta and Corgentech.
The Motley Fool December 6, 2004 Brian Gorman	Pill-Popping Nation Americans are using more prescription drugs. Unfortunately for big pharma investors, pharmaceutical companies' benefits from these trends are tempered by other factors.
Wired December 2004 Douglas Starr	The Cuban Biotech Revolution Embargo or no, Castro's socialist paradise has quietly become a pharmaceutical powerhouse. (They're still working on the capitalism thing.)
The Motley Fool December 3, 2004 W.D. Crotty	One Hot Biotech Stock Biomira reports favorable Phase II test results, sending the stock up 146%.
The Motley Fool December 3, 2004 Charly Travers	Sex Patch Returns to Lab FDA panel's safety concerns have sidetracked Proctor & Gamble's Intrinsa.
BusinessWeek December 13, 2004 Amy Barrett	On The Firing Line At Embattled Merck With claims against Vioxx mounting, Merck's general counsel Ken Frazier is in for the fight of his career.
BusinessWeek December 13, 2004 John Carey	How To Prevent Another Vioxx The tragedy should spur Congress and the FDA to improve the safety of new drugs.
BusinessWeek December 13, 2004 Bruce Einhorn	Go East, Big Pharma Drugmakers are expanding in China, but patents are still a worry.
BusinessWeek December 13, 2004 Gene G. Marcial	Given Imaging: A Camera You Can Swallow Embedded in a pill, a tiny wireless camera called PillCam, made by Israel's Given Imaging, is electrifying some investors.
BusinessWeek December 13, 2004 Gene G. Marcial	Rich Suitors May Come Courting Curis With Genentech, Johnson & Johnson, and Wyeth as its partners, tiny Curis is a "sitting duck" for a takeover as it develops drugs to combat a number of diseases. One hedge-fund manager puts Curis' buyout value at $9 a share.
<Older 1591-1600 Newer> Return to current articles.